% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stttner:306220,
      author       = {S. Stättner and K. Soreide and J. Hallet and C. M. Grana
                      and S. Partelli and K. Herrmann$^*$ and A. Brandl},
      title        = {{T}heranostics in surgical oncology.},
      journal      = {European journal of surgical oncology},
      volume       = {52},
      number       = {1},
      issn         = {0748-7983},
      address      = {Burlington, Mass.},
      publisher    = {Harcourt},
      reportid     = {DKFZ-2025-02449},
      pages        = {111187},
      year         = {2025},
      abstract     = {Theranostics is a method where molecules that target
                      surface structures in tumors are coupled with different
                      radioisotopes, allowing them to bind to tumor cells for
                      detection (diagnostic) and elimination (therapeutic). In the
                      case of neuroendocrine tumors (NET), peptides targeting
                      somatostatin receptors (SSTR) are most commonly used for
                      this purpose. These peptides are, for example, coupled with
                      68Ga for diagnostic and 177Lu for therapeutic purposes. This
                      allows SSTR-positive tumors to be detected with high
                      sensitivity and treated effectively, which is particularly
                      beneficial in cases where surgery (alone) is not feasible.
                      However, theranostic procedures can also be used to guide
                      surgical procedures or - in the context of a neoadjuvant
                      approach - increase resectability. Other therapies currently
                      in development aim to increase antitumor effectiveness or
                      aim to combat tumors which are resistant to other
                      radiopharmaceutical therapies (RPT) using new isotopes and
                      SSTR-targeting peptides or combining RPT with other drugs.
                      Modern radiological diagnostics, as well as the production
                      and use of radiopharmaceuticals, require costly equipment
                      and specialized procedures and are therefore not accessible
                      to most patients around the world. However, the expansion of
                      the repertoire of studied and approved theranostics promises
                      to make these highly effective treatments available to more
                      patients. The following review intends to provide an
                      overview of current questions about theranostics with
                      relevance to surgical oncology.},
      subtyp        = {Review Article},
      keywords     = {For submission (Other) / NET (Other) / Neuroendocrine tumor
                      (Other) / Nuclear medicine (Other) / Oncologic surgery
                      (Other) / Radiopharmaceutic therapy (Other) / Surgical
                      oncology (Other) / Theranostics (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41242087},
      doi          = {10.1016/j.ejso.2025.111187},
      url          = {https://inrepo02.dkfz.de/record/306220},
}